R Jokinen1, R Rinnankoski-Tuikka2, S Kaye1, L Saarinen3, S Heinonen1, M Myöhänen1, E Rappou1, S Jukarainen1, A Rissanen1,4, A Pessia5, V Velagapudi5, K A Virtanen6, E Pirinen2, K H Pietiläinen1,7. 1. Obesity Research Unit, Research Programs Unit, Diabetes and Obesity, University of Helsinki, Biomedicum Helsinki, Helsinki, Finland. 2. Research Programs Unit, Molecular Neurology, University of Helsinki, Biomedicum Helsinki, Helsinki, Finland. 3. Research Programs Unit, Genome-Scale Biology, University of Helsinki, Biomedicum Helsinki, Helsinki, Finland. 4. Department of Psychiatry, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland. 5. Metabolomics Unit, Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland. 6. Turku PET Centre, Turku University Hospital and University of Turku, Turku, Finland. 7. Endocrinology, Abdominal Center, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland.
Abstract
OBJECTIVES: We investigated whether (1) subcutaneous adipose tissue (SAT) mitochondrial capacity predicts weight loss success and (2) weight loss ameliorates obesity-related SAT mitochondrial abnormalities. METHODS: SAT biopsies were obtained from 19 clinically healthy obese subjects (body mass index (BMI) 34.6±2.7 kg m-2) during a weight loss intervention (0, 5 and 12 months) and from 19 lean reference subjects (BMI 22.7±1.1 kg m-2) at baseline. Based on 1-year weight loss outcome, the subjects were divided into two groups: continuous weight losers (WL, n=6) and weight regainers (WR, n=13). Main outcome measures included SAT mitochondrial pathways from transcriptomics, mitochondrial amount (mitochondrial DNA (mtDNA), Porin protein levels), mtDNA-encoded transcripts, oxidative phosphorylation (OXPHOS) proteins, and plasma metabolites of the mitochondrial branched-chain amino-acid catabolism (BCAA) pathway. SAT and visceral adipose tissue (VAT) glucose uptake was measured with positron emission tomography. RESULTS: Despite similar baseline clinical characteristics, SAT in the WL group exhibited higher gene expression level of nuclear-encoded mitochondrial pathways (P=0.0224 OXPHOS, P=0.0086 tricarboxylic acid cycle, P=0.0074 fatty acid beta-oxidation and P=0.0122 BCAA), mtDNA transcript COX1 (P=0.0229) and protein level of Porin (P=0.0462) than the WR group. Many baseline mitochondrial parameters correlated with WL success, and with SAT and VAT glucose uptake. During WL, the nuclear-encoded mitochondrial pathways were downregulated, together with increased plasma metabolite levels of BCAAs in both groups. MtDNA copy number increased in the WR group at 5 months (P=0.012), but decreased to baseline level between 5 and 12 months (P=0.015). The only significant change in the WL group for mtDNA was a reduction between 5 and 12 months (P=0.004). The levels of Porin did not change in either group upon WL. CONCLUSIONS: Higher mitochondrial capacity in SAT predicts good long-term WL success. WL does not ameliorate SAT mitochondrial downregulation and based on pathway expression, may paradoxically further reduce it.Data availability:The transcriptomics data generated in this study have been deposited to the Gene Expression Omnibus public repository, accession number GSE103769.
OBJECTIVES: We investigated whether (1) subcutaneous adipose tissue (SAT) mitochondrial capacity predicts weight loss success and (2) weight loss ameliorates obesity-related SAT mitochondrial abnormalities. METHODS: SAT biopsies were obtained from 19 clinically healthy obese subjects (body mass index (BMI) 34.6±2.7 kg m-2) during a weight loss intervention (0, 5 and 12 months) and from 19 lean reference subjects (BMI 22.7±1.1 kg m-2) at baseline. Based on 1-year weight loss outcome, the subjects were divided into two groups: continuous weight losers (WL, n=6) and weight regainers (WR, n=13). Main outcome measures included SAT mitochondrial pathways from transcriptomics, mitochondrial amount (mitochondrial DNA (mtDNA), Porin protein levels), mtDNA-encoded transcripts, oxidative phosphorylation (OXPHOS) proteins, and plasma metabolites of the mitochondrial branched-chain amino-acid catabolism (BCAA) pathway. SAT and visceral adipose tissue (VAT) glucose uptake was measured with positron emission tomography. RESULTS: Despite similar baseline clinical characteristics, SAT in the WL group exhibited higher gene expression level of nuclear-encoded mitochondrial pathways (P=0.0224 OXPHOS, P=0.0086 tricarboxylic acid cycle, P=0.0074 fatty acid beta-oxidation and P=0.0122 BCAA), mtDNA transcript COX1 (P=0.0229) and protein level of Porin (P=0.0462) than the WR group. Many baseline mitochondrial parameters correlated with WL success, and with SAT and VAT glucose uptake. During WL, the nuclear-encoded mitochondrial pathways were downregulated, together with increased plasma metabolite levels of BCAAs in both groups. MtDNA copy number increased in the WR group at 5 months (P=0.012), but decreased to baseline level between 5 and 12 months (P=0.015). The only significant change in the WL group for mtDNA was a reduction between 5 and 12 months (P=0.004). The levels of Porin did not change in either group upon WL. CONCLUSIONS: Higher mitochondrial capacity in SAT predicts good long-term WL success. WL does not ameliorate SAT mitochondrial downregulation and based on pathway expression, may paradoxically further reduce it.Data availability:The transcriptomics data generated in this study have been deposited to the Gene Expression Omnibus public repository, accession number GSE103769.
Authors: Lovisa E Johansson; Anders P H Danielsson; Hemang Parikh; Maria Klintenberg; Fredrik Norström; Leif Groop; Martin Ridderstråle Journal: Am J Clin Nutr Date: 2012-05-30 Impact factor: 7.045
Authors: Cyrus Jahansouz; Federico J Serrot; Brigitte I Frohnert; Rocio E Foncea; Robert B Dorman; Bridget Slusarek; Daniel B Leslie; David A Bernlohr; Sayeed Ikramuddin Journal: Obes Surg Date: 2015-12 Impact factor: 4.129
Authors: Kirsi H Pietiläinen; Sanna Kaye; Anna Karmi; Laura Suojanen; Aila Rissanen; Kirsi A Virtanen Journal: Br J Nutr Date: 2012-08-31 Impact factor: 3.718
Authors: Adil Mardinoglu; John T Heiker; Daniel Gärtner; Elias Björnson; Michael R Schön; Gesine Flehmig; Nora Klöting; Knut Krohn; Mathias Fasshauer; Michael Stumvoll; Jens Nielsen; Matthias Blüher Journal: Sci Rep Date: 2015-10-05 Impact factor: 4.379
Authors: Kirsi H Pietiläinen; Jussi Naukkarinen; Aila Rissanen; Juha Saharinen; Pekka Ellonen; Heli Keränen; Anu Suomalainen; Alexandra Götz; Tapani Suortti; Hannele Yki-Järvinen; Matej Oresic; Jaakko Kaprio; Leena Peltonen Journal: PLoS Med Date: 2008-03-11 Impact factor: 11.069
Authors: Ioannis G Lempesis; Rens L J van Meijel; Konstantinos N Manolopoulos; Gijs H Goossens Journal: Acta Physiol (Oxf) Date: 2019-06-02 Impact factor: 6.311
Authors: Birgitta W van der Kolk; Maheswary Muniandy; Dorota Kaminska; Marcus Alvarez; Arthur Ko; Zong Miao; Armand Valsesia; Dominique Langin; Maija Vaittinen; Mirva Pääkkönen; Riikka Jokinen; Sanna Kaye; Sini Heinonen; Kirsi A Virtanen; Daniel P Andersson; Ville Männistö; Wim H Saris; Arne Astrup; Mikael Rydén; Ellen E Blaak; Päivi Pajukanta; Jussi Pihlajamäki; Kirsi H Pietiläinen Journal: J Clin Endocrinol Metab Date: 2021-04-23 Impact factor: 5.958